Ce chapitre est structuré différemment. Il n'y a donc pas de "questions essentielles" répertoriées comme telles.
1 Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med 2003 ; 348 : 2599-608.
2De Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction. Circulation 1999 ; 99 : 779-85.
3 Brouns F, Bjork I, Frayn KN, et al. Glycaemic index methodology. Nutrition Research Reviews 2005 ; 18 ; 145-71.
4 Jenkins DJ, Kendall CW, Augustin LS, et al. Glycemic index : Overview of implications in health and disease. Am J Clin Nutr 2002 ; 76 : 266S-73S.
5McMillan-Price J, Petocz P, Atkinson F, O'neill K, Samman S, Steinbeck K, Caterson I, Brand-Miller J. con weight loss and cardiovascular risk reduction in overweight and obese young adults: a randomized controlled trial. Arch Intern Med. 2006 Jul 24;166(14):1466-75.
6Kaye Foster-Powell, Susanna HA Holt, and Janette C Brand-Miller. International table of glycemic index and glycemic load values: 2002. Am. J. Clinical Nutrition, 2002; 76: 5 - 56.
7Kaye Foster-Powell, Susanna HA Holt, and Janette C Brand-Miller. International table of glycemic index and glycemic load values: 2002. Am. J. Clinical Nutrition, 2002; 76: 5 - 56.
8Howard D. Sesso; Ralph S. Paffenbarger; I-Min Lee. Physical Activity and Coronary Heart Disease in Men- The Harvard Alumni Health Study. Circulation. 2000;102:975-980.
9Blair SN, Kohl HW, Barlow CE, Paffenbarger RS, Gibbons LW, Macera CA. Changes in physical fitness and all-cause mortality. A prospective study of healthy and unhealthy men. JAMA 1995;273:1093-8.
10Hedblad B, Ogren M, Isacsson SO, Janzon L. Reduced cardiovascular mortality risk in male smokers who are physically active. Results from a 25-year follow-up of the prospective population study men born in 1914. Arch Intern Med 1997;157:893-9.
11Manson JE, Hu FB, Rich-Edwards JW et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med 1999;341:650-658.
12Griffiths TL, Burr ML, Campbell IA et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet 2000;355:362-8.
13Diabetes prevention program researche groupe. Reduction in the incidence of type 2 diabetes with lifestyle intervention of metformin. N Engl J Med 2002;346:393-403.
14Michael P. Stern; Ken Williams and Steven M. Haffner. Identification of Persons at High Risk for Type 2 Diabetes Mellitus: Do We Need the Oral Glucose Tolerance Test ? Ann Intern Med. 2002;136:575-581.
15Youfa Wang, Eric B Rimm, Meir J Stampfer, Walter C Willett, and Frank B Hu. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men1–3. Am J Clin Nutr 2005;81:555– 63.
16Peto R; Darby S; Deo H; Silcocks P; Whitley E; Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000 Aug 5;321(7257):323-9.Godtfredsen NS; Prescott E; Osler M. Effect of smoking reduction on lung cancer risk. JAMA 2005;294:1505-10.
17Nystrom L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Ryden S, Andersson I, Bjurstam N, Fagerberg G, Frisell J, et al. Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet 1993;341:973-8.
18Nystrom L Andersson I Bjurstam N et al. Long-term effects of mammography screeining : updated overview of the Swedish randomised trials. Lancet 2002;359:909-19.
19Van Dijck JA, Verbeek AL, Beex LV, Hendriks JH, Holland R, Mravunac M, Straatman H, Werre JM. Breast-cancer mortality in a non-randomized trial on mammographic screening in women over age 65. Int J Cancer 1997;70(2):164-8.
2016-year mortality from breast cancer in the UK Trial of Early Detection of Breast Cancer. Lancet 1999 Jun 5;353:1909-14.
21Wallin KL, Wiklund F, Angstrom T et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999;341:1633-8.
22Gerber S. Gremlich S. Vaccin prophylactique anti-VPH : «un grand pas pour l’humanité et…» des questions pour notre société ! Revue médicale suisse 2006 ; 84.
23 Munoz N; Bosch FX; de Sanjose S; Herrero R; Castellsague X; Shah KV; Snijders PJ; Meijer. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003 Feb 6;348(6):518-27.
24Mayrand MH, Duarte-Franco E, Coutlee F, Rodrigues I, Walter SD, Ratnam S, Franco EL; CCCaST Study Group. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST).Int J Cancer. 2006 Aug 1;119(3):615-23.
25Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA. 2002 Oct 9;288(14):1749-57
26ANDEM. Pratique des frottis cervicaux pour le dépistage du cancer du col. Recommandations et références médicales 1995;T2:9-24.Quinn M et al. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. Br Med J 1999;318:904-8.
27Stuart GCE, McGregor SE, Duggan MA, Nation JG. Review of the screening history of Alberta women with invasive cervical cancer. Canadian Medical Association Journal, 1997 ; 157 : 513-9.
28 Koutsky LA, Ault K, Wheeler CM, et al. A controlled trial of human papillomavirus type 16 vaccine. N Engl J Med 2002 ; 347 : 1645-51.
29 Wallin KL, Wiklund F, Angstrom T, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999 ; 341 : 1633-8.
30 Gerber S, Gremlich S. Vaccin prophylactique anti-VPH : « un grand pas pour l’humanité et… » des questions pour notre société ! Rev Med Suisse 2006 ; 84 : 2401-6.
31Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003 ; 348 : 518-27.
32Mayrand MH, Duarte-Franco E, Coutlee F, Rodrigues I, Walter SD, Ratnam S, Franco EL ; CCCaST Study Group. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors : Design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer 2006 ; 119 : 615-23.
33Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities : Comparison of sensitivity, specificity, and frequency of referral. JAMA 2002 ; 288 : 1749-57.
34 ANDEM. Pratique des frottis cervicaux pour le dépistage du cancer du col. Recommandations et références médicales 1995 ; T2 : 9-24.
35 Stuart GCE, McGregor SE, Duggan MA, Nation JG. Review of the screening history of Alberta women with invasive cervical cancer. Canadian Medical Association Journal 1997 ; 157 : 513-9.
36 Koutsky LA, Ault K, Wheeler CM, et al. A controlled trial of human papillomavirus type 16 vaccine. N Engl J Med 2002 ; 347 : 1645-51.
37Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006 ; 56 : 106-30.
38 Larsson SC, Rafter J, Holmberg L, et al. Red meat consumption and risk of cancers of the proximal colon, distal colon and rectum : The Swedish Mammography Cohort. Int J Cancer 2005 ; 113 : 829-34.
39 Sanjoaquin MA, Appleby PN, Thorogood M, et al. Nutrition, lifestyle and colorectal cancer incidence : A prospective investigation of 10’998 vegetarians and non-vegetarians in the United Kingdom. Br J Cancer 2004 ; 90 : 118-21.
40 Zisman AL, Nickolov A, Brand RE, et al. Associations between the age at diagnosis and location of colorectal cancer and the use of alcohol and tobacco : Implications for screening. Arch Intern Med 2006 ; 166 : 629-43.
41Larsson SC, Orsin, N, Wok A. Diabetes mellitus and risk of colorectal cancer : A meta-analysis. J Natl Cancer Ist 2005 ; 97 : 1679-87.
42 Reid FD, Mercer PM, Harrison M, Bates T. Cholecystectomy as a risk factor for colorectal cancer : A meta-analysis. Scand J Gastroenterol 1996 ; 31 : 160-9.
43 Todoroki I, Friedman GD, Slattery ML, et al. Cholecystectomy and the risk of colon cancer. Am J Gastroenterol 1999 ; 94 : 41-6.
44Park Y, Hunter DJ, Spiegelman D, Bergkvist L, Berrino F, van den Brandt PA, Buring JE, Colditz GA, Freudenheim JL, Fuchs CS, Giovannucci E, Goldbohm RA, Graham S, Harnack L, Hartman AM, Jacobs DR Jr, Kato I, Krogh V, Leitzmann MF, McCullough ML, Miller AB, Pietinen P, Rohan TE, Schatzkin A, Willett WC, Wolk A, Zeleniuch-Jacquotte A, Zhang SM, Smith-Warner SA. Dietary fiber intake and risk of colorectal cancer : A pooled analysis of prospective cohort studies. JAMA 2005 ; 294 : 2849-57.
45 Michels KB, Willett WC, Fuchs CS, et al. Coffee, tea, and caffeine consumption and incidence of colon and rectal cancer. J Natl Cancer Inst 2005 ; 97 : 282-92.
46Schatzkin A, Lanza E, Corle D, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 2000 ; 342 : 1149-55.
47Peters U, Sinha R, Chatterjee N, et al. Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme. Lancet 2003 ; 361 : 1491-5.
48 Giovannucci E, Stampfer MJ, Colditz GA, et al. Multivitamin use, folate, and colon cancer in women in the Nurses’ Health Study. Ann Intern Med 1998 ; 129 : 517-24.
49 Wei EK, Giovannucci E, Selhub J, et al. Plasma vitamin B6 and the risk of colorectal cancer and adenoma in women. J Natl Cancer Inst 2005 ; 97 : 684-92.
50 Shaukat A, Scouras N, Schunemann HJ. Role of supplemental calcium in the recurrence of colorectal adenomas: a metaanalysis of randomized controlled trials. Am J Gastroenterol 2005; 100:390-4.
51 Colditz GA, Cannuscio CC, Frazier AL. Physical activity and reduced risk of colon cancer: Implications for prevention. Cancer Causes Control 1997; 8:649-67.
52 Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333:609-114.
53 Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial.JAMA. 2005 Jul 6;294(1):47-55.
54 Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004; 90:635-7.
55 Cho E; Rosner BA; Feskanich D; Colditz GA. J Clin Oncol 2005 Apr 20;23(12):2669-75.
56 Blot WJ; McLaughlin JK; Winn DM; Austin DF; Greenberg RS; Preston-Martin S; Bernstein L; Schoenberg JB; Stemhagen A; Fraumeni JF Jr. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988 Jun 1;48(11):3282-7
57 Huang WY; Winn DM; Brown LM; Gridley G; Bravo-Otero E; Diehl SR; Fraumeni JF Jr; Hayes RB. Alcohol concentration and risk of oral cancer in Puerto Rico.Am J Epidemiol 2003 May 15;157(10):881-7.
58 Sweden. AU Lewin F; Norell SE; Johansson H; Gustavsson P; Wennerberg J; Biorklund A; Rutqvist LESmoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: a population-based case-referent study.Cancer 1998 Apr 1;82(7):1367-75.
59 Quinn M et al. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. Br Med J 1999;318:904-8.
60 Bovier P, Gallachi-Bouvier M. Les vaccinations chez les adultes en Suisse: le point de vue des médecins de premier recours et de leurs patients. OFSP 316.98.6766 1999
61 Office fédéral de la santé publique. Communiqué de presse 21 décembre 1992.
62 John TJ. The final stages of the global eradication of polio. New Engl J Med 2000343.
63 Groupe d'étude canadienne sur l'examen périodique. Guide canadien de médecine clinique préventive, Canadian Medical Association, Ottawa, septembre 1994.
64 Woo EJ, Miller NB, Ball R; VAERS Working GroupVaccine. Adverse events after hepatitis A B combination vaccine. Vaccine 2006 Mar 24;24(14):2685-91.
65 Hak E, van Essen GA, Buskens E, Stalman W, de Melker RA. Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in Utrecht, The Netherlands. J Epidemiol Community Health 1998;52:120-5.
66 Nichol KI, Lind A, Margoli KL and al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995;333:889-93
67 Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331(12):778-84
68 Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995;123(7):518-
69 Wilde JA, McMillan JA, Serwint J, Butta J, O'Riordan MA, Steinhoff MC. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA 1999;281(10):908-13.
70 Potter J, Stott DJ, Roberts MA, Elder AG, O'Donnell B, Knight PV, Carman WF. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis 1997;175:1-6.
71 Fine M, Smith M, Carson C et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994;154:2666-77.
72 Ketterer JP, Rochat TH. Vaccin anti-pneumococcique. Med Hyg 1999;57:2329-33.
73 Nuorti JP, Butler JC, Farley MM et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 2000;342:681-9.
74 Infections à pneumocoques invasifs en Suisse. Bulletin de l’Office fédéral de la Santé publique, 2000 : 20 : 381-5.
75Measles United States 1990. MMWR 1991 ; 40 : 369.
76 Measles Outbreak – Netherlands, April 1999-January 2000. MMWR 2000 ; 49 : 299-303.
77 Nakayama T, Onoda K. Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004. Vaccine 2007 ; 25 : 570-6.
78 Office fédéral suisse de la santé publique. ???
79De Quadros CA, Hersh BS, Nogueira AC, Carrasco PA, da Silveira CM. Measles eradication : Experience in the Americas. Bull World Health Organ 1998 ; 76(S2) : 47-52.
80Lydick E, Cook K, Turpin J, Melton M, Stine R, Byrnes C. Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density. Am J Manag Care. 1998 ; 4 : 37-48.
81Cadarette SM, Jaglal SB, Murray TM, McIsaac WJ, Joseph L, Brown JP ; Canadian Multicentre Osteoporosis Study. Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry. JAMA. 2001 ; 286 : 57-63.
82Black DM, et al. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 2001 ; 12 : 519.
83 Cummings S, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995 ; 332 : 767-73.
84 Taylor BC, Schreiner PJ, Stone KL, Fink HA, Cummings SR, Nevitt MC, Bowman PJ, Ensrud KE. Long-term prediction of incident hip fracture risk in elderly white women : Study of osteoporotic fractures. J Am Geriatr Soc 2004 ; 52 : 1479-86.
85Von Strauss E, Viitanen M, De Ronchi D, et al. Aging and the occurence of dementia : Findings from a population-based cohort with a large sample.
86Cholinesterase inhibition for Alzheimer disease : A meta-analysis of the tacrine trials. Dementia Trialists’ Collaboration. JAMA 1998 ; 280 : 1777-82.
87 Jelic V, Kivipelto M, Winblad B. Clinical trials in mild cognitive impairment. Lessons for the future. Neurol Neurosurg Psych 2006 ; 77 : 429-38.
88 Bibliomed. Prise en charge des patients déments. 1999 ; 134.
89 Risks and benefits for intracranial aneurysms in first-degree relatives of patients with sporadic subarachnoid hemorrage. The Magnetic Resonance Angiography in Relatives of Patients with Subarachnoid Hemorrhage Study Group. N Engl J Med 1999 ; 341 : 1344-50.
90Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med 1998 ; 339 : 364-9.
91Strom BL, Abrutyn E, Berlin JA, et al. Dental and cardiac risk factors for infective endocarditis. A population-based, case-control study. Ann Intern Med 1998 ; 129 : 761-9.
92The Multicentre Aneurysm Screening Study Group. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men : A randomised controlled trial. Lancet 2002 ; 360 : 1531-9.
93Fleming C ; Whitlock EP, Beil TL, Lederle FA. Screening for Abdominal Aortic Aneurysm : A Best-Evidence Systematic Review for the US Preventive Services Task Force. Ann Intern Med 2005 ; 142 : 203-11.
94Hoogendam A, Buntinx F, de Vet HC. The diagnostic value of digital rectal examination in primary care screening for prostate cancer : A meta-analysis. Fam Pract 1999 ; 16 : 621-6.
95Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men 1-3. Am J Clin Nutr 2005 ; 81 : 555- 63.
96 Rouiller D. Nouveaux critères diagnostiques et classification du diabète sucré. Med Hyg 1999 ; 57 : 1284-8.
97Peters AL, Davidson MB, Schriger DL, Hasselblad V. A clinical approach for the diagnosis of diabetes mellitus : An analysis using glycosylated hemoglobin levels. Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. JAMA 1996 ; 276 : 1246-52.
98 Nikolic J, Vadas L, Unger P, Krähenbühl B. La CDT, nouveau marqueur de la consommation d’alcool, est-elle un détecteur de l’alcoolisme ? Med Hyg 1994 ; 52 : 1938-41.
99Bill-Axelson A, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005 ; 352 : 1977-84.
100Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002;347:790-6.
101 Kundu SD, Roehl KA, Antenor JA, Catalona W, Nadler RB. Age-specific risk of prostate cancer if PSA is between the median value and commonly used biopsy thresholds. San Antonio, TX : American Urological Assoc ; 2005:258.
102Ross KS, Ballentine Carter H, Pearson JD, Guess HA. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 2000 ; 284 ; 1399-405.
103Walter L, Bertenthal D Lindquist K, et al. PSA screening among elderly men with limited life expectancies. JAMA 2006 ; 296 : 2336-42.
104Adams PC. Population screening of Hemochromatosis. Hepatology 1999 ; 29 : 1324-7.
105Balan V, Baldus W, Fairbanks V, et al. Screening hemochromatosis : A cost-effectiveness study based on 12’258 patients. Gastroenterology 1994 ; 107 : 453-9.
106 Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kushner JP. Prevalence of hemochromatosis among 11’065 presumably healthy blood donors. N Engl J Med 1988 ; 318 : 1355-62.
107El-Serag HB, Inadomi JM, Kowdley KV. Screening for hereditary hemochromatosis in sibling and children of affected patients. A cost-effectiveness analysis. Ann Intern Med 2000 ; 132 : 261-9.
108Mark DB, Shaw L, Harrell FE Jr, Hlatky MA, Lee KL, Bengtson JR, McCants CB, Califf RM, Pryor DB. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med 1991 ; 325(12) : 849-53.
109Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project : Overall design and findings from baseline screening. Lancet 1999 ; 354 : 99-105.
110Gleeson FV. Is screening for lung cancer using low dose spiral CT scanning worthwhile ? Thorax 2006 ; 61 : 5-7.
111Walker PP, Mitchell P, Diamantea F, Warburton CJ, Davies L. Effect of primary-care spirometry on the diagnosis and management of COPD. Eur Respir J 2006 ; 28 : 945-52.
112Eddy DM. Screening for colorectal cancer. Ann Intern Med 1990 ; 113 : 373-84.
113O’Brien MJ, Winawer SJ, Zauber AG, et al. The National Polyp Study : Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 1990 ; 98 : 371-9.
114 Rembacken BJ, Fujii T, Caairns A, et al. Flat and depressed colonic neoplasms : A prospective study of 1000 colonoscopies in the UK. Lancet 2000 ; 355 : 1211-4.
115Chappuis PO, Hutter P. CCR : dépistage adapté au risque et rôle du médecin traitant dans la prévention de ce cancer. Rev Med Suisse 2006 ; 2 : 1314-23.
116Rex DK, Johnson DA, Lieberman DA, et al. Colorectal cancer prevention 2000 : Screening recommendations of the American College of Gastroenterolgy. Am J Gastroenterol 2000 ; 95 : 868-77.
Helm JF, Sandler RS. Colorectal cancer screening. Med Clin N Am 1999 ; 83 : 1403-22.
Bond JH. Screening guidelines for colorectal cancer. Am J Med 1999 ; 106 : 7S-10S.
117Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 2001 ; 345 : 555-60.
118Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polypectomy Study Workgroup. N Eng J Med 1993 ; 329 : 1977-81.
119Rex DK, Johnson DA, Lieberman DA, et al. Colorectal cancer prevention 2000 : Screening recommendations of the American College of Gastroenterology. Am J Gastro 2000 ; 95 : 868-77.
120Lieberman DA, Weiss DG, Bond JH. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000 ; 343 : 162-8.
121Rex DK, Rahmani EY, Haseman JH, et al. Relative sensitivity of colonoscopy and barium enema for detection of colorectal cancer in clinical practice. Gastroenterology 1997 ; 112 : 17-23.
122 Nelson RL, Persky V, Turyk M. Time trends in distal colorectal cancer subsite location related to age and how it affects choice of screening modality. J Surg Oncol 1998 ; 69 : 235-8.
123Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003 ; 95 : 1276-99.
124Waye JD, Lewis BS, Yessayan S. Colonoscopy : A prospective report of complications. J Clin Gastroenterol 1992 ; 15 : 347-51.
125 Dominitz JA, Provenzale D. Patients preferences and quality of life associated with colorectal cancer screening. Am J Gastroenterol 1997 ; 92 : 2171-8.
126Rex DK, Cummings OW, Helper DJ, et al. 5-year incidence of adenomas after negative colonoscopy asymptomatics average-risk persons. Gastroenterology 1996 ; 111 : 1178-81.
127Selby JV, Friedman GD, Quesenberry CP Jr, et al. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Eng J Med 1992 ; 326 : 653-7.
128Rex DK, Johnson DA, Lieberman DA, et al. Colorectal cancer prevention 2000 : Screening recommendations of the American College of Gastroenterology. Am J Gastro 2000 ; 95 : 868-77.
129 Lieberman DA. Cost-effectiveness model for colon cancer screening. Gastroenterology 1995 ; 109 : 1781-90.
Provenzale D, Homan RK, Oddone EZ. Screening colonoscopy in average risk individuals is cost-effective compared with other practices. Am J Gastroenterol 1999 ; 94 : 2683.
130Rex DK, Johnson DA, Lieberman DA, et al. Colorectal cancer prevention 2000 : Screening recommendations of the American College of Gastroenterology. Am J Gastro 2000 ; 95 : 868-77.
131Rex, DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997 ; 112 : 24-8.
132Rex DK, Johnson DA, Lieberman DA, et al. Colorectal cancer prevention 2000 : Screening recommendations of the American College of Gastroenterology. Am J Gastro 2000 ; 95 : 868-77.
133Selby JV, Friedman GD, Quesenberry CP Jr, et al. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Eng J Med 1992 ; 326 : 653-7.
134 Schoenfeld P, Cash B, Flood A, et al. Colonoscopic screening of average-risk women for colorectal neoplasia. N Engl J Med 2005 ; 352 : 2061-8.
135Stewart BT, Keck JO, Duncan AV, et al. Difficult or incomplete flexible sigmoidoscopy : Implications for a screening programme. Aus N Z J Surg 1999 ; 69 : 19-21.
136 Rex DK, Lehman GA, Ulbright TM, et al. The yield of a second screening flexible sigmoidoscopy in average-risk persons after one negative examination. Gastroenterology 1994 ; 106 : 593-5.
137 Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992 ; 326 : 658-62.
138Rex DK, Johnson DA, Lieberman DA, et al. Colorectal cancer prevention 2000 : Screening recommendations of the American College of Gastroenterology. Am J Gastro 2000 ; 95 : 868-77.
139Kewenter J, Brevinge H, Engaras B, et al. The yield of flexible sigmoidoscopy and double contrast barium enema in the diagnosis of neoplasms in the large bowel in patients with a positive hemoccult test. Endoscopy 1995 ; 27 : 159-63.
140 Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Eng J Med 1993 ; 328 : 1365-71.
141Kronborg O, Fenger C, Olsen J, et al. Randomized study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996 ; 348 : 1467-71.
142Delco F, Sonnenberg A. Limitations of the faecal occult blood test in screening for colorectal cancer. Ital J Gastroenterol Hepatol 1999 ; 31 : 119-26.
143Winawer SJ, Flehinger BJ, Schottenfeld D, Miller, DG. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst 1993 ; 85 : 1311-8.
144Ahlquist DA, Wieand HS, Moertel CG, et al. Accuracy of fecal occult blood test screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA 1993 ; 269 : 1262-7.
145Lieberman DA, Smith FW. Screening for colon malignancy with colonoscopy. Am J Gastroenterol 1991 ; 86 : 946-51.
146Rex DK, Rahmani EY, Haseman JH, et al. Relative sensitivity for colonoscopy and barium enema for detection of colorectal cancer in general practice. Gastroenterology 1997 ; 112 : 17-23.
Schrock TR. Colonoscopy versus barium enema in the diagnosis of colorectal cancer and polyps. Gastrointestinal Endosc Clin N AM 1993 ; 3 : 585-610.
147Hara AK, Johnson CD, Reed JE, et al. Detection of colorectal polyps with CT colograpy : Initial assessment of sensitivity and specificity. Radiology 1997 ; 205 : 59-65. Medline 147.
148Cotton PB, Durkalski VL, Pineau BC, et al. Computed tomographic colonography (virtual colonoscopy) : A multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. JAMA 2004 ; 291 : 1713-9.
149Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P, De La Chapelle A, Mecklin JP. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000 ; 118 : 829-34.
150Rex DK, Lieberman D. ACG colorectal cancer prevention action plan : Update on CT-colonography. Am J Gastroenterol 2006 ; 101 : 1410-3.
151Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992 ; 326 : 658-62.
152Jeffery GM, Hickey BE, Hider P. Follow-up strategies for patients treated for non-metastatic colorectal cancer (Cochrane Review). Cochrane Database Syst Rev 2002 ; CD002200.
153Butterly LF, Chase MP, Pohl H, et al. Prevalence of clinically important histology in small adenomas. Clin Gastroenterol Hepatol 2006 ; 4 : 343-8.
154Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer : A population-based study. N Engl J Med 1990 ; 323 : 1228-33.
155Baxter NN, Tepper JE, Durham SB, et al. Increased risk of rectal cancer after prostate radiation : A population-based study. Gastroenterology 2005 ; 128 : 819-24.
156Stewart M, Macrae FA, Williams CB. Neoplasia and ureterosigmoidostomy : A colonoscopy survey. Br J Surg 1982 ; 69 : 414-6.
157Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 2001 ; 96 : 2992-3003.
158AU Lu KH, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, Bandipalliam P, Chen LM, Allen B, Conrad P, Terdiman J, Sun C, Daniels M, Burke T, Gershenson DM, Lynch H, Lynch P, Broaddus RR SO. Gynecologic cancer as a « sentinel cancer » for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 2005 ; 105 : 569-74.
159Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P, De La Chapelle A, Mecklin JP. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000 ; 118 : 829-34.
160Maple JT, Boardman LA. Genetics of colonic polposis. Clin Gastroenterol and Hepatol 2006 ; 4 : 831-5.
161Dunlop MG. Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polypolis, juvenile polyposis, and Peutz-Jeghers syndrome. Gut 2002 ; 51 (Suppl 5) : V21-7.
162Leighton JA, Shen B, Baron TH. ASGE guideline : Endoscopy in the diagnosis and treatment of inflammatory bowel disesase. Gastrointestinal Endoscopy 2006 ; 63 ; 558-65.
163Rex DK, Johnson DA, Lieberman DA, et al. Colorectal cancer prevention 2000 : Screening recommendations of the American College of Gastroenterology. Am J Gastro 2000 ; 95 : 868-77.
164Davila R, Rajan E, Baron TH. ASGE guideline : Colorectal cancer screening and surveillance. Gastrointestinal Endocopy 2006 ; 63 ; 558-65.
165Winawer S, Zauber AG, Flechter RH, et al. Guidelines for colonoscopy surveillance after polypectomy : A consensus update by the US multi-society task force on colorectal cancer and the american cancer society. Gastroenterology 2006 ; 130 ; 1872-85.
166Rex DK, Kahi CJ, Levin B, et al. Guidelines for colonoscopy surveillance after cancer resection : A consensus updatre by the american cancer society and the US multi-society task force on colorectal cancer. Gastroenterology 2006 ; 130 : 1865-71.
167Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991 ; 83 ; 356-62.
168Laurier D, Nguyen PC, Cazelles B, Segond PJ. Estimation of CHD risk in a French working population using a modified Framingham model. Clin Epidemiol. 1994 ; 47 : 1353-64.
169Conroy RM, Pyorala K, Fitzgeralda AP, Sansc S, Menottid A, De Backere G, De Bacquere D, Ducimetière P, Jousilahtig P, Keilh U, Njølstadi I, Oganovj RG, Thomsenk T, Tunstall-Pedoel H, Tverdalm A, Wedeln H, Whincupo P, Wilhelmsenn L, Grahama IM, on behalf of the SCORE project group 1. Estimation of ten-year risk of fatal cardiovascular disease in Europe : The SCORE project. European Heart Journal 2003 ; 24 : 987-1003.
170The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins. in vascular disease. N Engl J Med 2006 ; 345 : 1567-77.
171Lloyd-Jones DM, Nam BH, D’Agostino RB, Levy D, Murabito JM, Wang TJ, Wilson PWF, O’Donnell CJ. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. A prospective study of parents and offspring. JAMA 2004 ; 291 : 2204-11.
172Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med 2003 ; 348 : 2599-608.
173De Backer, et al. European guidelines on cardiovascular disease prevention in clinical practice : Third Joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice. European Heart Journal 2003 ; 24 : 1601.
174 Riesen WF, Darioli R, Noseda G, Bertel O, Buser P. Recommandations pour la prévention de l’athérosclérose. Bulletin des médecins suisses 2005 ; 86 : 2055.
175Stampfer MJ, Hu FB, Manson JE, et al. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000 ; 343 : 16-22.
176Willcox BJ, He Q, Chen R, et al. Midlife risk factors and healthy survival in men. JAMA 2006 ; 296 : 2343-50.
177Primatesta P, Poulter N. Lipid concentrations and the use of lipid lowering drugs : Evidence from a national cross-sectional survey. BMJ 2000 ; 321 : 1322-5.
178Roberts CK, Barnard RJ. Effects of exercise and diet on chronic disease. J Appl Physiol 2005 ; 98 : 3-30. http://jap.physiology.org/cgi/content/full/ 98/1/3
179Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 343 : 16-22.
180Ribera AP, McKenna J, Riddoch C. Physical activity promotion in general practices of Barcelona : A case study. Health Educ Res 2006 ; 21 : 538-48.
181Prochaska JO, Velicer WF, Redding C, Rossi JS, Goldstein M, DePue J, Greene GW, Rossi SR, Sun X, Fava JL, Laforge R, Rakowski W, Plummer BA. Stage-based expert systems to guide a population of primary care patients to quit smoking, eat healthier, prevent skin cancer, and receive regular mammograms. Prev Med 2005 ; 41 : 406-16.
182Fichtenberg C, Glantz SA. Association of the california tobacco control program with declines in cigarette consumption and mortality from heart disease. NEJM 2000 ; 343 : 1772-7.
183Albert CM, Mittleman MA, Chae CU, Lee IM, Hennekens CH, Manson JE. Triggering of sudden death from cardiac causes by vigorous exertion. NEJM 2000 ; 343 : 1355-61.
184Holvoet P, Kritchevsky SB, Tracy RP, Mertens A, Rubin SM, Butler J, Goodpaster B, Harris TB. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes 2004 ; 53 : 1068-73.
185Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J, Shimamura K, Kimura J, Michishita I, Suzuki T, Nagai R. Circulating oxidized low density lipoprotein levels : A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 2000 ; 20 : 2243-7.
186McMillan-Price J, Petocz P, Atkinson F, O’neill K, Samman S, Steinbeck K, Caterson I, Brand-Miller J. Comparison of 4 diets of varying glycemic load on weight loss and cardiovascular risk reduction in overweight and obese young adults : A randomized controlled trial. Arch Intern Med 2006 ; 166 : 1466-75.
187Hauswirth CB, Scheeder MR, Beer JH. High omega-3 fatty acid content in alpine cheese : The basis for an alpine paradox. Circulation 2004 ; 6 ; 109 : 103-7.
188De Lorgeril M, Salen P, Martin JL, Mamelle N. Effect of a mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease. Insights into the cardioprotective effect of certain nutriments. J Am Coll Cardiol 1996 ; 28 : 1103-8.
189Estruch R, Martinez-Gonzalez MA, Corella D, Salas-Salvado J, Ruiz-Gutierrez V, Covas MI, Fiol M, Gomez-Gracia E, Lopez-Sabater MC, Vinyoles E, Aros F, Conde M, Lahoz C, Lapetra J, Saez G, Ros E. Effects of a Mediterranean-style diet on cardiovascular risk factors : A randomized trial. Ann Intern Med 2006 ; 145 : 1-11.
190Liu S, Stampfer MJ, Hu FB, Giovannucci E, Rimm E, Manson JE, Hennekens CH, Willett WC. Whole-grain consumption and risk of coronary heart disease : Results from the Nurses’ Health Study. Am J Clin Nutr 1999 ; 70 : 412-9.
191Rimm EB, Ascherio A, Giovannucci E, Spiegelman D, Stampfer MJ, Willett WC. Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. JAMA 1996 ; 14 ; 275 : 447-51.
192Joshipura KJ, Ascherio A, Manson JE, Stampfer MJ, Rimm EB, Speizer FE, Hennekens CH, Spiegelman D, Willett WC. Fruit and vegetable intake in relation to risk of ischemic stroke. JAMA 1999 ; 282 : 1233-9.
193Watts GF, Lewis B, Brunt JN, Lewis ES. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas’ Atherosclerosis Regression Study (STARS). Lancet 1992 ; 339 : 563-9.
194Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease : A meta-analysis of randomized controlled trials. Am J Med 2002 ; 112 : 298-304.
195Berger K, Ajani UA, Kase CS, et al. Light-to-moderate alcohol consumption and risk of stroke among US male physicians. N Engl J Med 1999 ; 341 : 1557-64.
196Gaziano JM, Gaziano TA, Glynn RJ, Sesso HD, Ajani UA, Stampfer MJ, Manson JE, Hennekens CH, Buring JE. Light-to-moderate alcohol consumption and mortality in the Physicians’ Health Study enrollment cohort. J Am Coll Cardiol 2000 ; 35 : 96-105.
196Opie LH, Lecour S. The red wine hypotesis : From concepts to protective signalling molecules. Eur Heart J 2007 ; 28 : 1683-93.
197Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson JE, Rosner B, Hunter DJ, Hennekens CH, Speizer FE. Smoking cessation in relation to total mortality rates in women. A prospective cohort study. Ann Intern Med 1993 ; 119 : 992-1000.
198Hermanson B, Omenn GS, Kronmal RA, Gersh BJ. Beneficial six-year outcome of smoking cessation in older men and women with coronary artery disease. Results from the CASS registry. N Engl J Med 1988 ; 319 : 1365-9.
199Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained release bupropion, a nicotine patch or both for smoking cessation. N Engl J Med 1999 ; 340 : 685-91.
200Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006 ; 166 : 1561-8.
201Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men. A sex-specific meta-analysis of randomized controlled trials. JAMA 2006 ; 295 : 306-13.
202Patrono C, Garcia Rodriguez L, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005 ; 353 : 2373-83.
203Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995 ; 333 : 1301-7.
204LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease : A meta-analysis of randomized controlled trials. JAMA 1999 ; 282 : 2340-6.
205Hebert PR, Moser M, Mayer J, Glynn RJ, Hennekens CH. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993 ; 153 : 578-81.
206van den Hoogen PC, Feskens EJ, Nagelkerke NJ, et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med 2000 ; 342 : 1-8.
207Sytkowski PA, D’Agostino RB, Belanger AJ, et al. Secular trends in long-term sustained hypertension, long-term treatment, and cardiovascular mortality. The Framingham Heart Study 1950 to 1990. Circulation 1996 ; 93 : 697-703.
208Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events : Results of prospectively-designed overviews of randomised trials. Lancet 2003 ; 362 : 1527-35.
209Materson BJ, Reda DJ, Preston RA, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, et al. Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 1995 ; 155 : 1757-62.
210Hebert PR, Fiebach N, Eberlein KA, et al. The community-based randomized trials of pharmacologic treatment of mild-to-moderate hypertension. Am J Epidemiol 1988 ; 127 : 581-90.
211Hebert PR, Moser M, Mayer J, et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993 ; 153 : 578-81.
212Hebert PR, Moser M, Mayer J, et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993 ; 153 : 578-81.
213Hebert PR, Fiebach N, Eberlein KA, et al. The community-based randomized trials of pharmacologic treatment of mild-to-moderate hypertension. Am J Epidemiol 1988 ; 127 : 581-90.
214 http://www.hbroussais.fr/cgi-bin/fram.p
215European guidelines for hypertension. J Hypertens 2003 ; 21 : 1011-53.
216Stamler R, Stamler J, Grimm R, et al. Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial – the Hypertension Control Program. JAMA 1987 ; 257 : 1484-91.
217Diabetes prevention program group. Reduction in incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 ; 346 : 393-403.
218David JA, Jenkins DM, Thomas MS, Wolever M Sc, Rodney H, Taylor RH, et al. Glycemic index of foods : A physiological basis for carbohydrate exchange. Am. J. Clin Nutr 1981 ; 34 : 362-6.
219McMillan-Price J, Petocz P, Atkinson F, O’neill K, Samman S, Steinbeck K, Caterson I, Brand-Miller J. Comparison of 4 diets of varying glycemic load on weight loss and cardiovascular risk reduction in overweight and obese young adults : A randomized controlled trial. Arch Intern Med 2006 ; 166 : 1466-75.
220Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 837-53.
221Felson DT, Zhang Y, Hannan MT, et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993 ; 329 : 1141-6.
222McNagny SE. Prescribing hormone replacement therapy for menopausal symptoms. Ann Intern Med 1999 ; 131 : 605-16.
223Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998 ; 280 : 605-13.
224Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998 ; 280 : 605-13.
225WHI. Risks and benefits of estrogen plus progestin in healthy postmenopausal women : Principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002 ; 288 : 321-33.
226Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995 ; 273 : 199-208.
227Breast cancer and hormone replacement therapy : collaborative reanalysis of data from 51 epidemiological studies of 52’705 women with breast cancer and 108’411 women without breast cancer. Collaborative group on hormonal factors in breast cancer. Lancet 1997 ; 350 : 1047-59.
228Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996 ; 348 : 983-7.
229Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation. A meta-analysis of randomized controlled trials. JAMA 2005 ; 293 : 2257-64.
230Black DM, Cummings SR, Karpf D. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996 ; 348 : 1535-41.
231 http://www.has-sante.fr/portail/upload/docs/ application/pdf/osteoporose_synthese.pdf. Site accédé le 17 janvier 2007.
232Ettinger B, Black DM, Mitlack BH, et al. Reduction of vertebral fracture risk in postmenauposal women with osteoporosis treated with raloxifene : Results from a 3-year randomized clinical trial. Multiple outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999 ; 282 : 637-45.
233 Eisen, A, Dhesy, S. A meta-analysis of randomized trials of tamoxifen for the prevention of breast cancer (abstract). Proc Am Soc Clin Oncol 2003 ; 22 : 98a.
234Barret-Connor E, Mosa L, Collins P, et al. Effects of raloxifen on cardiovascular events and breast cancer in postmoenopausal women. N Engl J Med 2006 ; 355 : 125-37.
235Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000 ; 342 : 1266-71.
236Grossberg PM, Brown DD, Fleming MF. Brief physician advice for high-risk drinking among young adults. Annals of Family Medicine 2004 ; 2 : 474-80.
237Whitworth AB, Fischer F, Lesch OM, Nimmerrichter A, Oberbauer H, Platz T, Potgieter A, Walter H, Fleischhacker WW. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996 ; 347 : 1438-42.
238Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics : Results of a placebo-controlled trial. Am J Psychiatry 1999 ; 156 : 1758-64.
